Furthermore, the interaction between the outcomes and MSI status remained significant, suggesting that, even if some patients with MSI-L/MSS GC may benefit from immunotherapy (mainly those with PD-L1 positive and/or high tumor mutation burden), the efficacy and activity of immunotherapy in the MSI-H arm is higher compared with the overall MSI-L/MSS counterpart. This evidence concerns the gene CD274 and neoplasm.